Why the FDA's peptide list changes how you should source

The FDA has been reviewing which peptides licensed compounding pharmacies can legally work with. That process has moved several compounds off the allowable list, and the effects reach into the research supply chain. If you handle these compounds at the bench, the changes are worth understanding in concrete terms.

What the FDA's compound review actually does

Compounding pharmacies in the U.S. fall into two categories: 503A facilities (smaller, producing patient-specific batches) and 503B facilities (larger-scale operations). Both are allowed to mix formulations using raw ingredients, but only from an approved bulk drug substance list. The FDA reviews compounds on that list through a tiered evaluation that considers medical need, available safety data, and manufacturing feasibility.

Compounds that fail to clear the review get moved to a restricted category. For 503A pharmacies, this means the compound can no longer be used in patient-specific compounding. BPC-157 is one example that ended up in this restricted group. TB-500 (thymosin beta-4) has faced similar regulatory attention. The pharmacy dispensing pathway for those specific compounds closed. Research-grade peptide synthesis labs operate under a separate framework, supplying researchers with bench materials rather than dispensing formulations to patients.

That structural difference is what keeps the research supply chain operating even when compounding pharmacy rules change.

Why the pharmacy and research supply chains diverge

A compounding pharmacy makes a finished product for a specific person to receive. The FDA watches that process closely because a human being is at the end of it. A peptide synthesis lab produces a raw material for laboratory use. The researcher is the customer, and the compound is a research input.

Your sourcing decisions follow different rules than a compounding pharmacy's formulary choices. But regulatory attention on a compound category still has a secondary effect: it raises the bar on documentation and purity standards across the whole market. Suppliers who can't back their products with clean analytical data lose ground when buyers start asking harder questions.

That means purity documentation matters more now. Regulatory pressure is one reason. Research reproducibility is another. Both push in the same direction.

Reading a COA and knowing what counts

A Certificate of Analysis (COA) is the document that tells you what's actually in your vial. A reliable COA shows two things. First, HPLC purity (HPLC stands for high-performance liquid chromatography, a lab method that separates everything in a sample and measures how much of each component is present). Second, mass spectrometry confirmation (a test that checks the compound's molecular weight against the expected value for that peptide) to verify you have what you ordered.

HPLC purity above 98% is the standard benchmark for research-grade peptide work. Below that threshold, you're working with unknowns. Truncated sequences from incomplete synthesis, residual solvents, and acetate salts can all appear in lower-purity batches and affect how your samples behave during reconstitution and storage.

When your supplier changes, or a new lot arrives from an unfamiliar source, running an independent purity check, rather than relying entirely on the supplier's COA, is a reasonable step. Supply disruptions caused by regulatory shifts often push buyers toward new sources quickly, and new sources carry unknown track records.

Bench habits that keep your data clean

The fundamentals of handling research peptides stay constant regardless of what happens at the regulatory level. A few practices are worth keeping consistent:

• Store lyophilized powder cold and dark. Lyophilized means freeze-dried. Most peptides ship this way and stay stable longest at -20°C or below, protected from light exposure.
• Use bacteriostatic water for multi-use vials. Bacteriostatic water contains 0.9% benzyl alcohol, which prevents microbial growth in a reconstituted (liquid) vial. Plain sterile water provides no such protection once a vial has been opened.
• Work out your concentration before adding diluent. Knowing exactly how many micrograms per microliter you're working with keeps your measurements consistent and your results comparable across experiments.
• Log every batch. Record the lot number, the COA purity figures, the reconstitution date, and the storage location. If a compound's regulatory status changes mid-project, your records show exactly what material you used and when.

The FDA's review cycle will keep moving. Compounds will continue to be evaluated, and the allowable lists will keep shifting. Sourcing from suppliers who provide complete analytical documentation and handling each batch correctly from arrival gives your research the best chance of holding up regardless of what the regulatory calendar looks like next.

Frequently asked questions

Are peptides like BPC-157 banned from research after FDA review?

The FDA's compounding review restricts which compounds pharmacy compounders can dispense, not research-grade use. Peptide synthesis labs supplying researchers operate under a separate regulatory framework.

What purity level should a research peptide COA show?

HPLC purity above 98% is the standard benchmark for research-grade peptides. The COA should also include mass spectrometry confirmation matching the compound's expected molecular weight.

What diluent should I use when reconstituting peptides for multi-use research vials?

Bacteriostatic water (0.9% benzyl alcohol) is the standard choice for multi-use vials. The benzyl alcohol inhibits microbial growth after the vial is opened, which plain sterile water cannot do.

Prompted by this coverage at Google News →

Related from our lab: the pen · cartridges · bacteriostatic water · reconstitution calculators

Shared by PreppinPeppers for research, educational, and demonstration awareness only. We link to third-party coverage; we do not endorse it, and nothing here is medical advice or a recommendation to use any substance in humans or animals. Our products are sold for laboratory research use only.

More in our bacteriostatic water and diluents collection.

What the research community gets wrong about the FDA peptide compounding list and research sourcing

• "Off the compounding list" does not mean "banned everywhere." When a compound like BPC-157 is moved out of the pharmacy compounding pathway, that limits what a compounding pharmacy can dispense to a patient. It does not decide whether a synthesis lab can supply the same material as a research input for the bench.
• A flagged category is not a proof of danger. When the FDA groups a nominated substance with significant safety questions, that reflects the bar for the patient-dispensing pathway. It is a different question from how the material is identified, verified, and handled as a research reagent in the lab.
• A COA is a claim on paper, not a measurement you made. A line that reads 98% HPLC is only as good as the lab that produced it. When a lot arrives from a new or unfamiliar source (something that happens fast when supply shifts), an independent purity check on your own instrument is a reasonable step before the material enters your data.
• A high purity number does not mean zero impurities. Deletion (truncated) sequences left over from synthesis, residual solvents, and acetate salts can still ride along in a vial. These can change how a sample behaves during reconstitution and storage, even when the headline percentage looks clean.
• Regulatory news does not rewrite bench fundamentals. Cold and dark storage of lyophilized powder, and the correct diluent for a multi-use vial, matter the same regardless of which list a compound sits on this quarter.

From our bench: If you have run your own HPLC check on a lot after switching suppliers, we want the side-by-side. Tell us the compound, the purity the COA claimed, the purity your own run reported, and the lot date, and we will fold it into our sourcing notes so other researchers can see how often the paper number and the measured number line up.

Sources

1. Bacteriostatic Water for Injection, USP , FDA/DailyMed label (0.9% benzyl alcohol)
2. Duerkop et al., Biotechnol J 2018 , Impact of Cavitation, High Shear Stress and Air/Liquid Interfaces on Protein Aggregation
3. Sigma-Aldrich (Merck) , Handling and Storage Guidelines for Peptides and Proteins
4. PubChem, BPC-157 compound record (CID 9941957)
5. GenScript, Peptide Purity technical guidance (HPLC purity grades and deletion-sequence impurities)